Gi-Hoon Nam
Chief Executive Officer Shiftbio
Dr. Gi-Hoon Nam is the founder and Chief Executive Officer of SHIFTBIO, a delivery platform company that engineers cell-derived natural nanoparticles (NNPs) into programmable vehicles for RNA, ASO, and protein therapeutics. He holds an MD/PhD background in nanomedicine and tumor immunology, and serves as a Principal Investigator at Korea University College of Medicine. His scientific contributions span membrane-engineered vesicle scaffolds, brain-penetrant delivery design, and structure-prediction-driven platform development. At SHIFTBIO he leads the company’s NNP Trinity platform (NSM Scaffold, NNP Design AI, and a validated 3D bioreactor manufacturing process) and its two delivery lines, B-NNP for CNS indications and I-NNP for inflammation, fibrosis, and oncology. The company’s lead immunology assets, SBI-101 and SBI-102, have received Orphan Drug Designation and completed a Pre-IND meeting, with IND submission and Phase 1 entry on track.
Seminars
- Presenting the NNP Trinity platform, a structure-prediction-driven approach that combines an NSM membrane engineering scaffold, AI-guided design of protein assembly, and a validated 3D bioreactor process for scalable, clinical-grade production of cell-derived natural nanoparticles
- Exploring the B-NNP brain shuttle, a dock-and-transcytose dual-targeting design in which Transferrin Receptor 1 drives receptor-mediated transcytosis across the blood-brain barrier while a second motif anchors the particle to a diseased-brain glycoprotein, enabling deep parenchymal delivery rather than perivascular accumulation
- Outlining applied oligonucleotide delivery with in vivo data on ASO and siRNA cargo loaded into B-NNP, including amyloid-beta reduction in a 5XFAD Alzheimer’s model after systemic IV dosing, with extension to additional CNS targets
